Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics is a medical technology company that saw a significant rise in expenses in Q4 FY25 due to merger consolidation but has also been actively developing its channel and offerings, leading to a 16% revenue growth in 2025 and a gross margin increase to 78% in Q4. While net losses have widened due to the transition to a new distribution strategy, this short-term impact is expected to lead to better economics and larger revenue opportunities in the future, with a focus on achieving cashflow breakeven. However, there may be potential dilution in shares as the company needs additional capital for operations and debt servicing. Despite these near-term challenges, operational efficiency could continue to improve, and revenue could grow, leading to a positive outlook for Vivos Therapeutics.

Vivos Therapeutics is facing a variety of fundamental challenges that contribute to a negative outlook on the stock. Despite the potential for high returns, the company faces risks in securing regulatory approvals, gaining market acceptance, and maintaining long-term compliance rates. Furthermore, its current business model and revenue stream appear unlikely to sustain the company's operations, indicating that additional capital is needed. The company's high debt levels and low cash flow also pose significant risks to its financial stability and ability to execute long-term growth strategies.